Panoramica dell'azienda
Galectin Therapeutics Inc. operates as a clinical stage biopharmaceutical company dedicated to the research and development of novel therapies targeting fibrotic diseases, oncology, and other medical conditions. The firm functions within the healthcare sector, specifically the biotechnology industry, where its primary asset is the lead product candidate belapectin (GR-MD-02), a galectin-3 inhibitor currently undergoing Phase 2b/3 clinical trials. In terms of scale, the company maintains a market capitalization of $151.40M while employing 9 individuals to drive its development pipeline. The combination of a market cap of $151.40M and the absence of reported annual revenue indicates that the company is in a pre-commercialization phase, suggesting its current valuation is driven primarily by the potential future success of its clinical trials rather than current operational cash flows or established product sales.
Salute finanziaria
The company reports a net income of $-30,974,000 for the trailing twelve months, while revenue and EBITDA figures are not available due to the nature of its clinical-stage operations. The significant gap between the reported net income and the absence of revenue highlights a cost structure dominated by research and development expenditures rather than cost of goods sold associated with manufacturing. Free cash flow stands at $-20,904,750, which signifies that the company is burning cash to fund its clinical programs and operational infrastructure without generating operating cash inflows. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability or scaled revenue generation to cover its direct and indirect costs. On the balance sheet, cash reserves total $17.72M, which is substantially lower than the total debt obligation of $137.72M, revealing a highly leveraged financial position. The debt-to-equity ratio is not applicable, further emphasizing the capital intensity of the business model relative to shareholder equity. Liquidity is assessed via a current ratio of 2.42, suggesting the company possesses sufficient current assets to cover short-term liabilities, though this metric does not fully capture the long-term solvency challenges posed by high debt levels. Return on Equity and Return on Assets are both not applicable or negative; specifically, Return on Assets is -67.8%, which reveals that the company's assets are currently generating significant losses relative to the capital invested.
Valutazione del valore
Trailing P/E and Forward P/E metrics are presented as not applicable or -1.37 respectively, reflecting the absence of positive earnings and the negative forward earnings projection implied by the current trajectory. The price-to-book ratio is recorded at -1.17, a negative figure that indicates the market valuation is below the company's book value, a common characteristic for biotechnology firms with significant liabilities or negative equity positions. Alternative valuation metrics such as price-to-sales and EV/EBITDA are not available, as the company has not yet generated revenue streams sufficient to calculate these standard financial multiples. The stock has experienced significant volatility, trading between a 52-week low of $1.21 and a 52-week high of $7.13. Without a specific current price provided in the data, the exact percentage deviation from the 52-week high cannot be calculated, but the wide range between $1.21 and $7.13 demonstrates substantial price movement over the last year. The beta value is 1.04, which implies that the stock's price volatility is slightly higher than the broader market, moving 4% more than the market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available, as the company has not yet produced the revenue or earnings data required to calculate these growth rates. Since revenue and earnings figures are not applicable, no comparison can be made regarding whether earnings are growing faster or slower than revenue. The company does not pay dividends, evidenced by a dividend yield of not applicable and a payout ratio of 0.0%, meaning the firm retains all available capital to reinvest into its drug research and development activities rather than distributing income to shareholders. This reinvestment strategy is typical for clinical-stage biopharmaceutical companies that prioritize advancing their clinical trial portfolio over generating immediate shareholder returns. The overall growth and income profile is defined by a focus on capital appreciation potential through clinical milestones rather than current dividend income or consistent revenue expansion.